8 years of historical data (2018–2025) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Avidity Biosciences, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $2.2B | $9.9B | $3.2B | $661M | $1.2B | $985M | $553M | — | — |
| Enterprise Value | $1.9B | $9.6B | $3.0B | $486M | $828M | $676M | $232M | — | — |
| P/E Ratio → | -2.97 | — | — | — | — | — | — | — | — |
| P/S Ratio | 118.92 | 529.62 | 297.77 | 69.12 | 125.49 | 105.59 | 81.46 | — | — |
| P/B Ratio | 1.20 | 5.88 | 2.28 | 1.32 | 2.00 | 2.58 | 1.81 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 514.27 | 278.22 | 50.79 | 89.74 | 72.49 | 34.23 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Avidity Biosciences, Inc. earns an operating margin of -3977.3%. Operating margins have compressed from -2464.4% to -3977.3% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -44.0% indicates the company is currently destroying shareholder equity.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 77.9% | 77.9% | 100.0% | 78.0% | 85.0% | -984.9% | -454.0% | 100.0% | -2125.9% |
| Operating Margin | -3977.3% | -3977.3% | -3477.4% | -2464.4% | -1939.6% | -1265.8% | -652.4% | -747.4% | -2769.9% |
| Net Profit Margin | -3650.4% | -3650.4% | -2957.7% | -2219.9% | -1886.3% | -1265.4% | -653.5% | -1066.6% | -3148.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -44.0% | -44.0% | -33.5% | -39.3% | -36.3% | -34.3% | -36.8% | — | — |
| ROA | -38.9% | -38.9% | -29.4% | -33.5% | -32.6% | -31.0% | -20.6% | -49.0% | -299.7% |
| ROIC | -42.8% | -42.8% | -37.0% | -61.6% | -83.6% | -303.2% | — | — | — |
| ROCE | -46.2% | -46.2% | -37.6% | -41.5% | -36.3% | -32.9% | -21.8% | -40.3% | — |
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $383M exceeds total debt of $95M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.06 | 0.06 | 0.00 | 0.02 | 0.02 | 0.03 | 0.00 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.17 | -0.15 | -0.35 | -0.57 | -0.81 | -1.05 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | -39.75 | — |
| Interest Coverage | — | — | — | — | — | — | -211.85 | -2.35 | -14.62 |
Net cash position: cash ($383M) exceeds total debt ($95M)
Short-term solvency ratios and asset-utilisation metrics
Avidity Biosciences, Inc.'s current ratio of 9.20x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 7.58x to 9.20x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.20 | 9.20 | 15.73 | 7.58 | 12.00 | 13.86 | 22.74 | 9.35 | 0.70 |
| Quick Ratio | 9.20 | 9.20 | 15.73 | 7.58 | 12.00 | 13.86 | 22.74 | 9.35 | 0.70 |
| Cash Ratio | 8.68 | 8.68 | 15.32 | 7.38 | 11.77 | 13.67 | 22.50 | 9.24 | 0.67 |
| Asset Turnover | — | 0.01 | 0.01 | 0.02 | 0.01 | 0.02 | 0.02 | 0.02 | 0.10 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 242.08 | 945.31 | 329.23 | 153.34 | 35.22 | 64.54 | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Avidity Biosciences, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $138M | $112M | $73M | $52M | $41M | $22M | $38M | $21M |
Compare RNA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| RNAYou | $2B | -3.0 | — | — | 77.9% | -3977.3% | -44.0% | -42.8% | — |
| ALNY | $44B | 142.9 | 81.4 | 94.7 | 81.8% | 13.5% | 73.3% | 19.1% | 5.3 |
| IONS | $13B | -34.1 | — | — | 98.3% | -40.5% | -70.7% | -12.2% | — |
| ARWR | $9B | -5186.1 | 76.1 | 55.4 | 97.1% | 11.9% | -0.5% | 7.2% | 6.9 |
| CRSP | $6B | -9.3 | — | — | -2642.3% | -18933.6% | -30.2% | -27.4% | — |
| BEAM | $3B | -35.1 | — | — | 84.0% | -274.6% | -8.1% | -33.6% | — |
| WVE | $2B | -19.9 | — | — | 100.0% | -101.9% | -77.9% | — | — |
| STOK | $2B | -22.1 | — | — | 100.0% | -277.3% | -45.8% | -206.8% | — |
| NTLA | $2B | -3.6 | — | — | — | — | -53.5% | — | — |
| ABUS | $895M | -12.3 | — | — | 100.0% | -1236.7% | -68.8% | -75.9% | — |
| PRME | $833M | -2.8 | — | — | 100.0% | -6787.4% | -136.9% | -260.5% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 8 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how RNA stacks up against sector leader Alnylam Pharmaceuticals, Inc..
Start ComparisonAvidity Biosciences, Inc.'s current P/E ratio is -3.0x. This places it at the 50th percentile of its historical range.
Avidity Biosciences, Inc.'s return on equity (ROE) is -44.0%. The historical average is -37.4%.
Based on historical data, Avidity Biosciences, Inc. is trading at a P/E of -3.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Avidity Biosciences, Inc. has 77.9% gross margin and -3977.3% operating margin.